Biopharmaceutical company Epizyme sets terms for $60 million IPO

By Renaissance Capital,

Shutterstock photo

Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Epizyme would command a market value of $375 million. 

Epizyme, which was founded in 2007 and booked $48 million in sales for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on March 22, 2013. Citi, Cowen & Company, and Leerink Swann are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: EPZM

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by